Skip to main content

Peer Review reports

From: A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

Original Submission
15 May 2011 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
11 Aug 2011 Reviewed Reviewer Report - Hui Gan
9 Sep 2011 Author responded Author comments - Mark McKeage
Resubmission - Version 3
9 Sep 2011 Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
Resubmission - Version 5
Submitted Manuscript version 5
6 Oct 2011 Author responded Author comments - Mark McKeage
Resubmission - Version 6
6 Oct 2011 Submitted Manuscript version 6
Publishing
7 Oct 2011 Editorially accepted
7 Oct 2011 Article published 10.1186/1471-2407-11-432

You can find further information about peer review here.

Back to article page